Kathy Yi compensation by year
Cerevel Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $384,710 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $2,720,766 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $395,693 |
| Total | $3,501,169 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cerevel Therapeutics Holdings, Inc. DEF 14A filed April 28, 2022, accession 0001193125-22-127554, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Cerevel Therapeutics Holdings, Inc. filed document, accession 0001193125-22-127554. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2022.
Cerevel Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| N. Anthony Coles | Chairperson and Chief Executive Officer (1) | $8,108,335 |
| Abraham Ceesay | President | $5,276,631 |
| Kathy Yi · this page | Former Chief Financial Officer | $3,501,169 |
| Raymond Sanchez | Chief Medical Officer | $3,416,287 |
| Scott Akamine | Chief Legal Officer and Corporate Secretary | $3,194,740 |
| John Renger | Chief Scientific Officer | $3,093,750 |
| Mark Bodenrader | Interim Chief Financial Officer, Vice President, Finance and Chief Accounting Officer | $1,312,994 |
The full Cerevel Therapeutics compensation record
free company briefThis page is one person within Cerevel Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Cerevel Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cerevel Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.